Medtentia International is a medical device company focused on developing first-generation transcatheter mitral valve repair solutions. Our minimally invasive technology has the potential to enable safer, faster, and less traumatic cardiac interventions for mitral regurgitation patients worldwide. Medtentia’s innovative helix ring technology has been carefully designed to fit the anatomy of the mitral valve. This allows fast and easy implantation and most importantly, restoration of the valve geometry leading to uncompromised clinical efficacy. With our catheter-based product, we expect to reduce the invasiveness, operation time, and morbidity associated with mitral valve repair operations. This would allow effective treatment of patients at any stage of mitral valve disease, including those who currently have no treatment options. Medtentia’s patented helix ring technology, which is currently at an advanced development stage, can be applied to interventional cardiology as well as to cardiac surgery. For more information, please visit us at www.medtentia.com.